• Giuseppe TridenteEmail author


Panitumumab (Vectibix®, Amgen) is a fully human IgG2k monoclonal antibody specifically directed to the human epithelial growth factor receptor (EGFR) present on normal and neoplastic epithelial cells. In September 2006, FDA granted an accelerated approval as a single agent for the treatment of EGFR-expressing metastatic colorectal cancer (mCRC) with disease progression or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.


Interstitial Lung Disease Mutate Type Biliary Tract Cancer Skin Toxicity Best Supportive Care 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_32_MOESM1_ESM.xls (62 kb)
Supplementary material 1 (XLS 62 kb)


  1. 1.
    Panitumumab (Vectibix®) BLA125147 Medical Review FDA, Sept 2006Google Scholar
  2. 2.
    Panitumumab (Vectibix®) WC500047707 Scientific Discussion EMEA, Dec 2007Google Scholar
  3. 3.
    Panitumumab (Vectibix®) SBD 105601 Health Canada, Dec 2008Google Scholar
  4. 4.
    Panitumumab (Vectibix®) WC5000118765 Variation Assessment Report EMEA, Mar 2011Google Scholar
  5. 5.
    Panitumumab (Vectibix®) Prescribing Information Amgen, Aug 2012Google Scholar
  6. 6.
    Panitumumab (Vectibix®) WC500047710 EPAR, EMEA Sept 2012Google Scholar
  7. 7.
    Voigt M, Braig F, Göthel M et al (2012) Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia 11:1023–1031Google Scholar
  8. 8.
    Perea S, Hidalgo M (2004) Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors. Clin Lung Cancer 6:S30–S34PubMedCrossRefGoogle Scholar
  9. 9.
    Cohenuram M, Saif MW (2007) Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18:7–15PubMedCrossRefGoogle Scholar
  10. 10.
    Messersmith WA, Hidalgo M (2007) Panitumumab, a monoclonal anti-epidermal growth factor receptor antibody in colorectal cancer: another one or the one? Clin Cancer Res 13:4664–4666PubMedCrossRefGoogle Scholar
  11. 11.
    Bardelli A, Siena S (2012) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254–1261CrossRefGoogle Scholar
  12. 12.
    Weeraratne D, Chen A, Pennucci JJ (2011) Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin Pharmacol 11:17–26PubMedCrossRefGoogle Scholar
  13. 13.
    Doi T, Tahara M, Yoshino T et al (2011) Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 41:210–216Google Scholar
  14. 14.
    Köhne C-H, Hofheinz R, Mineur L et al (2012) First-line panitumumab plus irinotecan/5-fluorouracil/Leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 138:65–72PubMedCrossRefGoogle Scholar
  15. 15.
    Thaler J, Karthaus M, Mineur L et al (2012) Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLDIRI treatment in a single-arm phase II study. BMC Cancer 12:438. doi: 10.1186/1471-2407-12-438 PubMedCrossRefGoogle Scholar
  16. 16.
    Mitchell EP, Piperdi B, Lacouture ME et al (2011) The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (skin toxicity evaluation protocol with panitumumab) by KRAS status. Clin Colorectal Cancer 10:333–339PubMedCrossRefGoogle Scholar
  17. 17.
    Ibrahim EM, Abouelkhair KM (2011) Clinical outcome of panitumumab for metastatic colorectal cancer with wild type KRAS status: a meta-analysis of randomized clinical trials. Med Oncol 28:S310–S317PubMedCrossRefGoogle Scholar
  18. 18.
    Zhou S-W, Huang Y–Y, Wei Y et al (2012) No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis. PLoS ONE 7:e50925. doi: 10.1371/journal.pone.0050925
  19. 19.
    Fuloria J (2012) Safety profiles of current angiogenic therapies for metastatic colorectal cancer. OncoTargets Ther 5:133–142CrossRefGoogle Scholar
  20. 20.
    Vermorken J, Stöhlmacher J, Oliner K et al (2011) Safety and efficacy of panitumumab (pmab) in HPV positive (+) and HPV negative (−) recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): analysis of the phase 3 SPECTRUM trial. XVI ECCO European Cancer Congress, Stockholm, abstract 25. EJC 47(S2):13Google Scholar
  21. 21.
    Burris H, Stephenson J, Otterson GA et al (2011) Safety and pharmacokinetics of motesanib in combination with panitumumab and gentamicine-cisplatin in patients with advanced cancer. J Oncol. doi: 10.1155/2011/853931 PubMedGoogle Scholar
  22. 22.
    Vlahovic G, Meadows KL, Uronis HE et al (2012) A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol 70:95–102PubMedCrossRefGoogle Scholar
  23. 23.
    Rosen LS, Puzanov I, Friberg G et al (2012) Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin Cancer Res 18:3414–3427PubMedCrossRefGoogle Scholar
  24. 24.
    Jensen LH, Lindebjerg J, Ploen J et al (2012) Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Ann Oncol 23:2341–2346PubMedCrossRefGoogle Scholar
  25. 25.
    Misale S, Yaeger R, Hobor S et al (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. doi: 10.1038/nature11156 PubMedGoogle Scholar
  26. 26.
    Mittmann N, Seung SJ (2011) Rash rates with EGFR inhibitors: meta-analysis. Curr Oncol 18:e54–e63PubMedGoogle Scholar
  27. 27.
    Foerster CG, Cursiefen C, Kruse FE (2008) Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea 27:612–614PubMedCrossRefGoogle Scholar
  28. 28.
    Saint-Jean A, Saintz de la Maza M, Morral M et al (2012) Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophthalmology 119:1798–1802Google Scholar
  29. 29.
    Petrelli F, Cabiddu M, Borgonovo K et al (2012) Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta analysis of randomized clinical trials. Ann Oncol 23:1672–1679PubMedCrossRefGoogle Scholar
  30. 30.
    Wang J, Zhao Z, Barber B et al (2011) A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer. BJC 104:1848–1853PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations